Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Revenues (Details)

v3.23.1
Revenues (Details)
$ in Thousands
12 Months Ended
Mar. 16, 2021
USD ($)
Jan. 28, 2021
EUR (€)
Jan. 08, 2018
Mar. 31, 2015
USD ($)
Mar. 31, 2015
CAD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CAD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2019
USD ($)
Revenues (Details) [Line Items]                  
Payments       $ 1,292 $ 1,650        
Additional payments (in Dollars)             $ 2,000    
Payments percentage           16.50% 16.50%    
Up-front amount receive   € 250       $ 3,000      
Payables           6,000      
Amount received           1,500     $ 750
Additional and payments           500      
Distribution and supply agreement, description     Under the Distribution and Supply Agreement, the Company is entitled to € 1,500 thousand upon execution of the agreement. In addition, the Company is also entitled to milestone payments upon achieving certain clinical, launch and sales milestones, as follows: (i) € 300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and € 300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between € 750 thousand and € 1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis, and (iii) between € 300 thousand and up to €4,025 thousand upon meeting certain net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson in the territories and payment for the manufacturing Piclidenoson.            
Total payments           750      
Additional payments           $ 3,250      
Royalties 17.50% 30.00%              
Signature date   2 years              
Royalities, description   15%-40% royalties on net sales upon regulatory approval for veterinary use.              
Minimum [Member]                  
Revenues (Details) [Line Items]                  
Cost plus percentage           10.00%   10.00%  
Maximum [Member]                  
Revenues (Details) [Line Items]                  
Cost plus percentage           23.00%   23.00%  
Gebro Holding GmBH [Member]                  
Revenues (Details) [Line Items]                  
Amount received           $ 1,850   € 1,500,000  
Additional and payments           720   € 600,000  
CMS Medical Venture Investment Limited [Member]                  
Revenues (Details) [Line Items]                  
Up-front amount receive           2,000      
Payables           14,000      
Amount received           2,000      
Milestone payments           58,500      
Ewopharma [Member]                  
Revenues (Details) [Line Items]                  
Up-front amount receive $ 2,250                
Payables $ 40,450                
Amount received           $ 2,250